(Q52072195)

English

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.

scientific article published in October 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. (English)

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

17

object named as

C Blomqvist

1 reference

Europe PubMed Central

21 April 2018

15

object named as

H Holte

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

author name string

J Bergh

1

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

B Erikstein

3

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

E Lidbrink

4

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

H Lindman

5

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

P Malmström

6

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

P Kellokumpu-Lehtinen

7

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

N O Bengtsson

8

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

G Söderlund

9

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

G Anker

10

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

E Wist

11

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

S Ottosson

12

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

E Salminen

13

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

P Ljungman

14

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

J Nilsson

16

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

N Wilking

18

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

language of work or name

0 references

publication date

1 October 2000

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

356

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

1384-1391

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

9239

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Where next with stem-cell-supported high-dose therapy for breast cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical pharmacokinetics-pharmacodynamics of anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Tailored chemotherapy to equal toxicity: is it possible?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

FEC mobilized stem cells for high-dose therapy in breast cancer patients. SB6 9401 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comprehensive criteria for assessing therapy-induced toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute promyelocytic leukemia with t(15;17) following inhibition of DNA topoisomerase II

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902841-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(00)02841-5

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

1 reference

Europe PubMed Central

21 April 2018

http://europepmc.org/abstract/MED/11052580

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52072195&oldid=1584681538"